E
Erika L. Krick
Researcher at University of Pennsylvania
Publications - 30
Citations - 961
Erika L. Krick is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Lymphoma & Chemotherapy. The author has an hindex of 14, co-authored 30 publications receiving 751 citations. Previous affiliations of Erika L. Krick include Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours
Cheryl A. London,Tamra Mathie,Nicole Stingle,Craig A. Clifford,Siobhan Haney,Mary K. Klein,Linda Beaver,Kate Vickery,David M. Vail,Betsey Hershey,Susan Ettinger,Andrew Vaughan,Francisco J. Alvarez,Lorin Hillman,Mike Kiselow,Doug H. Thamm,Mary Lynn Higginbotham,Meredith Gauthier,Erika L. Krick,Brenda Phillips,Tracy Ladue,Pam Jones,Jeffery Bryan,Virginia L. Gill,Andrew Novasad,Lisa Fulton,Janet K. Carreras,C. J. McNeill,Carolyn J. Henry,Sarah Gillings +29 more
TL;DR: Preliminary evidence that toceranib exhibits CB in dogs with certain solid tumours is provided, although future prospective studies are necessary to define its true activity.
Journal ArticleDOI
Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival.
TL;DR: It is suggested that cytological evaluation of lymph nodes in dogs with mast cell tumours provides useful and valuable clinical information, and the results correlate with tumour grade and outcome thus providing a practical and non-invasive method for staging.
Journal ArticleDOI
Outcome and toxicity associated with a dose‐intensified, maintenance‐free CHOP‐based chemotherapy protocol in canine lymphoma: 130 cases
TL;DR: The results suggest that dose density is important, but likely relative, and needs to be adjusted according to the individual patient's toxicity for optimal outcome.
Journal ArticleDOI
CD40-Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma
Karin U. Sorenmo,Erika L. Krick,Christina M. Coughlin,Beth Overley,Thomas P. Gregor,Robert H. Vonderheide,Nicola J. Mason +6 more
TL;DR: Results suggest that cell-based CD40 cancer vaccination is safe and synergizes with chemotherapy to improve clinical outcome in canine NHL and underscore the unique value of clinical investigations in tumor-bearing companion animals.
Journal ArticleDOI
Evaluation of histological grade and histologically tumour‐free margins as predictors of local recurrence in completely excised canine mast cell tumours
Lindsay L. Donnelly,C. Mullin,Julie A. Balko,Michael H. Goldschmidt,Erika L. Krick,C. Hume,Dorothy Cimino Brown,Karin U. Sorenmo +7 more
TL;DR: It is hypothesized that HTFM width would correlate with risk for LR and high-grade tumours would require wider HTFM than low- grade tumours, but there is no association between HT FM width and LR.